Excellent video showing progression of atherosclerotic plaque, fibrous cap disruption, exposure of the lipid core & ensuing thrombosis. Can we identify new therapies that reduce ischemic vascular events without offsetting harm from increased risk of bleeding in these patients?..

Combining individual participant data from 5 RCTs we demonstrate a high residual risk of recurrent ischemic stroke and all-cause mortality in patients with AF and stroke despite OAC treatment, highlighting a major unmet need in this population. #NeuroTwitter #CardioTwitter

Very much looking forward to discussing the promising role of FXI(a) inhibition for secondary stroke prevention with valeria caso, Mike Sharma, John Eikelboom and Martin Dichgans at #ESOC2023 this afternoon. PHRI.ca Population Health Research Institute 🇨🇦 McMaster Stroke Program #neurotwitter

What a privilege to be on #ESOC2023 TV yesterday talking about diversity and inclusion in clinical trials with the greats valeria caso and Mike Sharma. Moderated by Joanna Wardlaw and Daniel Strbian. Lots of work to do and hoping we can do it together. Else C. Sandset

A new project to uncover the the determinants of post stroke cognitive decline with the talented Raed Joundi.

Important results for application of Boston Criteria. If trying to identify patients at high risk for future ICH, for instance in relation to risk-benefit of antithrombotic Rx, stick with v1.5 Andreas Charidimou MD, PhD @BleedingStroke David Seiffge Charlotte Cordonnier UCL Stroke Research #neurotwitter

Yago said that exercise should never stop even if you have too much work and grant applications. To get rid of the burden of work overload and deal better with the toxicity of some people: exercise, exercise, exercise, and have fun. Don't forget October, 1 movement for stroke

Delighted to see our most recent paper online. Check out our findings on #cmrt and #holter in #stroke CSB Jan Scheitz 🧠⚡️❤️ #strokeheart #brainheart Charité - Universitätsmedizin Berlin pubmed.ncbi.nlm.nih.gov/37353342/

Well said - characterizing etiology and prognosis is critical in ICH

A pleasure to work with such capable colleagues on this important trial of FXIa inhibition for stroke prevention

Optimal timing to resume anticoagulation after Intracranial Hemorrhage is a controversial topic ! Our latest paper reviewing the topic , definitely in need of a RCT. A shout out to our star research fellow Kareem M. El Naamani, MD Jefferson Neurosurgery Jefferson Health journals.lww.com/neurosurgery/f…

WSC 2023 is taking concrete actions to prioritize sustainability and embrace the Sustainable Development Goals (SDGs) principles. One of the most aspects is GOAL 5: Achieve gender equality and empower all women and girls. worldstrokecongress.org/sustainability…

It was a great privilege to explore the topic in this setting. Much to be done in this area.

It was a great privilege to be invited to present and meet with the accomplished group at the Cleveland Clinic. Thank you for your hospitality.

Excited to join Mike Sharma, valeria caso and Manesh Patel at #ISC24 for a dinner symposium on FXIa inhibitors for secondary stroke prevention on Tuesday Feb. 6th. Registration info 👇 Looking forward to seeing you there! McMaster University Department of Medicine AHA Science #stroke #neurotwitter

Registered for #ISC24 dinner sympo? Factor XI/XIa inhibitors for secondary stroke prevention in pts w/ischemic strokes & TIA risks, 2/6, 6pm MT onsite & online. mededotg.com/ISCfactorXIa AHA Science Manesh Patel Ashkan Shoamanesh Mike Sharma valeria caso Duke Heart

Interesting data. Quite consistent with our observations in the ANNEXa-I trial. PCC does not seem to provide any benefit in acute FXa inhibitor associated ICH.

Fantastic session - ESUS is evolving more than retiring

Huge shoutout to #PHRI scientist Mike Sharma (Mike Sharma) and the AXIOMATIC-SSP trial team! Their paper has been selected as European Stroke Org's Paper of the Month for Feb 2024! Check out the study's findings in The Lancet Neurology: thelancet.com/journals/laneu… McMaster University Department of Medicine #stroke #RCT

Nice work! 🏆 FYI for the trainees, Aristeidis Katsanos started this trial as a STROKE FELLOW McMaster Stroke Program